$100B in NIH-fund­ed re­search played an im­por­tant role in all 210 new drugs ap­proved over 7 years — study

The next time some­one chal­lenges the im­por­tance of NIH-fund­ed re­search in drug de­vel­op­ment, you might want to point them to a new study that high­lights the foun­da­tion­al role the In­sti­tutes plays in bio­phar­ma re­search.

The study — pub­lished in the Pro­ceed­ings of the Na­tion­al Acad­e­my of Sci­ences — con­cludes that every one of the 210 new mol­e­c­u­lar en­ti­ties ap­proved by the FDA be­tween 2010 and 2016 can source re­search back to NIH-fund­ed work. That is es­pe­cial­ly im­por­tant in fig­ur­ing the pub­lic con­text of first-in-class work, where ba­sic re­search played a sig­nif­i­cant role in the sci­en­tif­ic un­der­stand­ing of the tar­gets in­volved.

From the study by a team of re­searchers at Bent­ley Uni­ver­si­ty:

These da­ta demon­strate that a siz­able pub­lic-sec­tor in­vest­ment oc­curs be­fore the ap­proval of first-in-class NMEs, par­tic­u­lar­ly those dis­cov­ered us­ing tar­get­ed dis­cov­ery meth­ods (in­clud­ing re­com­bi­nant bi­o­log­i­cals). The scale of this in­vest­ment can be es­ti­mat­ed from the costs as­so­ci­at­ed with first-in-class NMEs ap­proved in 2010–2016 and their mol­e­c­u­lar tar­gets. These da­ta sug­gest that the pub­lic-sec­tor in­vest­ment in re­search un­der­ly­ing each first-in-class drug is as high as $839 mil­lion, with 89% of this cost as­so­ci­at­ed with tar­get re­search and 11% of the cost as­so­ci­at­ed with the first-in-class com­pound or fol­low-on com­pounds ap­proved from 2010–2016….

Over­all, this analy­sis sug­gests that as much as 20% of the NIH bud­get al­lo­ca­tion from 2000–2016 (more than $100 bil­lion) was as­so­ci­at­ed with pub­lished re­search that di­rect­ly or in­di­rect­ly con­tributed to NMEs ap­proved from 2010–2016.

The au­thors in par­tic­u­lar want­ed to ex­pand the scope of their re­search to make sure they were ac­count­ing for NIH-fund­ed stud­ies that were es­sen­tial to a drug tar­get, which doesn’t al­ways fac­tor in­to the patents used to pro­tect the com­mer­cial val­ue of each drug — a stan­dard that had been used in ear­li­er at­tempts to high­light the role of the NIH in drug de­vel­op­ment.

No one at the NIH is like­ly to get any kick­back from bio­phar­ma on this score. NIH fund­ing has been un­der the gun un­der Pres­i­dent Don­ald Trump, who’s been ready to sac­ri­fice re­search spend­ing in fa­vor of oth­er pri­or­i­ties. But the NIH bud­get has been saved by a bi­par­ti­san pha­lanx of elect­ed of­fi­cials in Con­gress who have ral­lied against the cuts. They’ll be back on the front­line of this de­bate now that Trump has sub­mit­ted a new bud­get this week that calls on law­mak­ers to flat­line spend­ing at the In­sti­tutes.

Those de­fend­ers just got some fresh am­mu­ni­tion for the fights to come.

Grow­ing ac­cep­tance of ac­cel­er­at­ed path­ways for nov­el treat­ments: but does reg­u­la­to­ry ap­proval lead to com­mer­cial suc­cess?

By Mwango Kashoki, MD, MPH, Vice President-Technical, and Richard Macaulay, Senior Director, of Parexel Regulatory & Access

In recent years, we’ve seen a significant uptake in the use of regulatory options by companies looking to accelerate the journey of life-saving drugs to market. In 2018, 73% of the novel drugs approved by the U.S. Federal Drug Administration (FDA) were designated under one or more expedited development program categories (Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval).ᶦ

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

As the world becomes increasingly dependant on Asia for the ingredients of its medicines, Sanofi sees business to be done in Europe.

The French drugmaker said it’s creating the world’s second largest active pharmaceutical ingredients (API) manufacturer by spinning out its six current sites into a standalone company: Brindisi (Italy), Frankfurt Chemistry (Germany), Haverhill (UK), St Aubin les Elbeuf (France), Újpest (Hungary) and Vertolaye (France). They have mapped out €1 billion in expected sales by 2022 and 3,100 employees for the new operations headquartered in France.

UP­DAT­ED: NGM Bio takes leap for­ward in crowd­ed NASH field

South San Francisco-based NGM Bio may have underwhelmed with its interim analysis of a key cohort from a mid-stage NASH study last fall — but stellar topline data unveiled on Monday showed the compound induced significant signs of antifibrotic activity, NASH resolution and liver fat reduction, sending the company’s stock soaring.

There are an estimated 50+ companies focused on developing drugs for non-alcoholic steatohepatitis, or NASH, a common liver disease that has long flummoxed researchers. The first wave of NASH drug developers struggled with efficacy as well as safety — and companies big and small have crashed and burned.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Mickey Kertesz, KidsandArtOrg via YouTube

Soft­Bank's newest, $165M biotech in­vest­ment looks for in­fec­tious traces in the blood

SoftBank has found its newest biotech investment.

The Japanese bank has invested $165 million into Karius, a company that uses blood tests to diagnose infectious diseases, as part of its new Vision Fund 2. The full scope of the new fund has yet to be announced, but the first and newly-beleaguered Vision Fund poured $100 billion into technology companies, including the biotechs Vir Biotechnology and Roivant and the sequencing company 10x Genomics.

Methicillin-resistant Staph aureus (Shutterstock)

FDA grants ‘break­through’ sta­tus to an­tibi­ot­ic al­ter­na­tive as Con­tra­Fect rush­es to join fight against su­per­bug

An experimental drug that promises to be the first anti-infective agent to prove superior to vancomycin — an antibiotic approved in 1958 — has notched the FDA’s “breakthrough” status.

ContraFect said the designation was based on Phase II data in which exebacase was tested against a superbug known as methicillin-resistant Staph aureus, or MRSA. In a subgroup analysis, the clinical responder rate at day 14 was 42.8% higher than that among those treated with standard of care, the company said (p=0.010).

Zhong Nanshan, CGTN via YouTube

Har­vard joins coro­n­avirus fight with $115 mil­lion and a high-pro­file Chi­nese part­ner

For two months, as the novel coronavirus swelled from a few early cases tied to a Wuhan market to a global epidemic, most of the world’s focus and dollars have flowed toward emergency initiatives: building vaccines at a record pace, plucking experimental antivirals out of freezers to see what sticks and immunizing mice for new antibodies.

Now a new and well-funded collaboration between Harvard and a top Chinese research institute will play the long game. In a 5-year, $115 million initiative backed by China Evergrande Group, researchers from the Harvard Medical School, Harvard T.H. Chan School of Public Health and Guangzhou Institute for Respiratory Health will study the virus in an effort to develop therapies against infections by the novel coronavirus, known as SARS–CoV-2, and to prevent new ones.

No­var­tis gets a boost in block­buster mul­ti­ple scle­ro­sis race with Roche

In the first step of what’s likely to be a long and uphill battle for the drugmaker, the FDA has accepted Novartis’s BLA submission for a new multiple sclerosis drug and given it priority review. The PDUFA date for the potential blockbuster drug is in June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 72,900+ biopharma pros reading Endpoints daily — and it's free.

Juergen Horn

An­i­mal health vet Juer­gen Horn makes new an­ti­body play for pets, rak­ing $15M in Se­ries A haul

Zoetis forked over $85 million in 2017 to acquire Nexvet Biopharma and its pipeline of monoclonal antibodies. Juergen Horn, Nexvet’s former chief product development officer, has now secured $15 million for his own biologic company for animals: Invetx.

Buoyed by emerging advances in gene therapies for humans, scientists have started looking at harnessing the technology for animals setting up companies such as Penn-partnered Scout Bio and George Church-founded Rejuvenate Bio. But akin to Nexvet, Invetx is working on leveraging the time-tested science of monoclonal antibodies to treat chronic diseases that afflict man’s best friend.

As coro­n­avirus out­break reach­es 'tip­ping point,' GSK lends ad­ju­vant tech to Chi­nese part­ner armed with pre­clin­i­cal vac­cine

As the coronavirus originating out of Wuhan spreads to South Korea, Italy and Iran, stoking already intense fears of a pandemic, GlaxoSmithKline has found another pair of trusted hands to place its adjuvant system. China’s Clover Biopharmaceuticals will add the adjuvant to its preclinical, protein-based vaccine candidate against SARS-CoV-2.

Clover, which is based in the inland city of Chengdu, boasts of a platform dubbed Trimer-Tag that produces covalently-trimerized fusion proteins. Its candidate, COVID-19 S-Trimer, resembles the viral spike (S)-protein found in the virus.